| Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire (NCT05817331) | Otsuka Australia Pharmaceutical Pty Ltd | 2022-06-28 |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS (NCT04878432) | Novartis Pharmaceuticals | 2022-03-17 |
| ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (NCT04639024) | Gwynn Long, M.D. | 2021-12-07 |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT05143996) | Cullinan Therapeutics Inc. | 2021-11-18 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) (NCT05168904) | Cyclacel Pharmaceuticals, Inc. | 2021-10-22 |
| Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome (NCT04912063) | AbbVie | 2021-06-25 |
| A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (NCT04812548) | Novartis Pharmaceuticals | 2021-05-31 |
| Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (NCT04603001) | Eli Lilly and Company | 2020-11-19 |
| A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome (NCT04608110) | Taiho Pharmaceutical Co., Ltd. | 2020-10-30 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (NCT04401748) | AbbVie | 2020-09-10 |
| TPO-Mimetic Use in Children for Hematopoietic Failure (NCT04478227) | Anjali Sharathkumar | 2020-08-18 |
| JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation (NCT04429191) | Jasper Therapeutics, Inc. | 2020-07-08 |
| Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT (NCT04284228) | NexImmune Inc. | 2020-02-20 |
| A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies (NCT06550713) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-22 |
| A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome (NCT03486353) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2019-10-01 |
| CPX-351 Therapy for MDS After Hypomethylating Agent Failure (NCT03957876) | Case Comprehensive Cancer Center | 2019-07-25 |
| Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (NCT03613532) | Jacqueline Garcia, MD | 2018-10-24 |
| A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes (NCT03516591) | Amphivena Therapeutics, Inc. | 2018-06-22 |
| A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia (NCT03600909) | Memorial Sloan Kettering Cancer Center | 2018-05-15 |
| Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (NCT03335943) | Chinese Society of Hematology | 2017-12-01 |
| Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (NCT03173937) | National Heart, Lung, and Blood Institute (NHLBI) | 2017-06-13 |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT (NCT02989844) | Masonic Cancer Center, University of Minnesota | 2017-04-12 |
| Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome (NCT02979366) | Institut de Recherches Internationales Servier | 2017-03-15 |
| Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (NCT02749708) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-01-30 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS (NCT02730299) | Gamida Cell ltd | 2016-12-16 |
| Myelodysplasic Syndromes and Risk Factors for Infection (NCT02905552) | Assistance Publique - Hôpitaux de Paris | 2016-09-01 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (NCT02790515) | St. Jude Children's Research Hospital | 2016-07-14 |
| Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (NCT02992860) | GWT-TUD GmbH | 2016-07-01 |
| The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients (NCT02648932) | University of Chicago | 2016-02-04 |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome (NCT01520805) | Cornerstone Pharmaceuticals | 2016-01-01 |
| Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS (NCT02626715) | Randy Windreich | 2015-09-04 |
| Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients (NCT02433483) | St. Jude Children's Research Hospital | 2015-05-22 |
| Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (NCT02269579) | Jazz Pharmaceuticals | 2015-04-01 |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (NCT02204020) | University of Pittsburgh | 2015-04-01 |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (NCT02240537) | Benovus Bio, Inc. | 2015-01-01 |
| Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome (NCT02920541) | Institut de Recherches Internationales Servier | 2015-01-01 |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation (NCT02259348) | St. Jude Children's Research Hospital | 2014-10-01 |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome (NCT02212561) | St. Jude Children's Research Hospital | 2014-08-01 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients (NCT02238925) | Jazz Pharmaceuticals | 2014-07-01 |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs (NCT02200380) | Celldex Therapeutics | 2014-07-01 |
| Darbepoetin Alfa MDS Companion Protocol (NCT02175277) | Amgen | 2014-06-12 |
| Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL (NCT02147873) | TetraLogic Pharmaceuticals | 2014-06-01 |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (NCT02143830) | Children's Hospital Medical Center, Cincinnati | 2014-04-01 |
| Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT (NCT01772953) | Center for International Blood and Marrow Transplant Research | 2013-09-01 |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) (NCT01842646) | H. Lee Moffitt Cancer Center and Research Institute | 2013-08-29 |
| Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients (NCT01929408) | Fred Hutchinson Cancer Center | 2013-07-19 |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment (NCT02099266) | University of Kansas Medical Center | 2013-06-01 |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM (NCT01816230) | Gamida Cell ltd | 2013-04-01 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| AML-MDS Novel Prognostic Tests Clinical Study (NCT01685619) | Nova Scotia Health Authority | 2012-10-02 |
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (NCT01413568) | Polyphor Ltd. | 2012-04-01 |
| Improving Blood Stem Cell Collection and Transplant Procedures (NCT01517035) | National Heart, Lung, and Blood Institute (NHLBI) | 2012-01-13 |
| Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS (NCT02124174) | Patrick Stiff | 2012-01-01 |
| Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome (NCT01422486) | Telik | 2011-10-01 |
| Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome (NCT01459159) | Telik | 2011-10-01 |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (NCT01342289) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-08-01 |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia (NCT01286038) | H. Lee Moffitt Cancer Center and Research Institute | 2011-04-06 |
| Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia (NCT01362036) | Tarix Pharmaceuticals | 2011-04-01 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies (NCT01221857) | Gamida Cell ltd | 2010-11-01 |
| Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (NCT01338337) | Asociación Andaluza de Hematología y Hemoterapia | 2010-11-01 |
| Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) (NCT01211691) | Humanigen, Inc. | 2010-09-01 |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (NCT01034657) | Novartis Pharmaceuticals | 2009-11-01 |
| Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome (NCT00977132) | Heinrich-Heine University, Duesseldorf | 2009-10-01 |
| Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders (NCT01224496) | Singapore General Hospital | 2009-07-01 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells (NCT01050764) | Everett Meyer | 2009-06-01 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant (NCT00796068) | Fred Hutchinson Cancer Center | 2009-02-24 |
| Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) (NCT00700206) | Telik | 2008-05-01 |
| Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (NCT00656617) | M.D. Anderson Cancer Center | 2008-04-01 |
| Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine (NCT00655395) | Viron Therapeutics Inc | 2008-03-01 |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) (NCT00502112) | Seagen Inc. | 2008-03-01 |
| Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood (NCT00923910) | National Cancer Institute (NCI) | 2008-02-22 |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies (NCT00566696) | St. Jude Children's Research Hospital | 2007-12-14 |
| Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome (NCT00542828) | Genzyme, a Sanofi Company | 2007-10-01 |
| Safety of ON 01910.Na in Patients With Myelodysplasia (NCT00533416) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-09-14 |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia (NCT00664677) | Erimos Pharmaceuticals | 2007-08-01 |
| Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies (NCT00673114) | Joanne Kurtzberg, MD | 2007-08-01 |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers (NCT00488592) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-06-01 |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation (NCT00672152) | Michael Morse, MD | 2007-06-01 |
| Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) (NCT00682799) | Charlotte Niemeyer, MD | 2007-04-01 |
| 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS (NCT00339196) | Assistance Publique - Hôpitaux de Paris | 2006-07-01 |
| Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome (NCT00270452) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-12-22 |
| MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank (NCT02537990) | Sunnybrook Health Sciences Centre | 2005-08-01 |
| Biology Studies of Hematologic Cancers (NCT00923442) | National Cancer Institute (NCI) | 2004-02-24 |
| Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) (NCT00225992) | Oncology Specialties, Alabama | 2004-02-01 |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies (NCT00145613) | St. Jude Children's Research Hospital | 2003-06-01 |
| Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies (NCT00186823) | St. Jude Children's Research Hospital | 2002-03-01 |